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Abstract
Background: We assessed the clinical utility of a first-degree breast cancer family history and polygenic risk score (PRS) to in-
form screening decisions among women aged 30-50 years. Methods: Two established breast cancer models evaluated digital
mammography screening strategies in the 1985 US birth cohort by risk groups defined by family history and PRS based on 313
single nucleotide polymorphisms. Strategies varied in initiation age (30, 35, 40, 45, and 50 years) and interval (annual, hybrid,
biennial, triennial). The benefits (breast cancer deaths averted, life-years gained) and harms (false-positive mammograms,
overdiagnoses) were compared with those seen with 3 established screening guidelines. Results: Women with a breast cancer
family history who initiated biennial screening at age 40 years (vs 50 years) had a 36% (model range¼ 29%-40%) increase in
life-years gained and 20% (model range¼ 16%-24%) more breast cancer deaths averted, but 21% (model range ¼ 17%-23%) more
overdiagnoses and 63% (model range¼ 62%-64%) more false positives. Screening tailored to PRS vs biennial screening from 50
to 74 years had smaller positive effects on life-years gained (20%) and breast cancer deaths averted (11%) but also smaller
increases in overdiagnoses (10%) and false positives (26%). Combined use of family history and PRS vs biennial screening from
50 to 74 years had the greatest increase in life-years gained (29%) and breast cancer deaths averted (18%). Conclusions: Our
results suggest that breast cancer family history and PRS could guide screening decisions before age 50 years among women
at increased risk for breast cancer but expected increases in overdiagnoses and false positives should be expected.
Routine mammography screening starting at age 45 or 50 years
has been shown to reduce population breast cancer mortality
for women at average risk (1). It remains uncertain whether the
current screening guidelines (2-4) are optimal for individual
women considering the variability in breast cancer risk at any
given age. The American Cancer Society (ACS) and the United
States Preventive Services Task Force (USPSTF) recommend that
women discuss their individual risk and screening options with
their healthcare providers before the age of 45 or 50 years, yet
there are limited data to inform such discussions. Risk-based
screening has been proposed as a way to inform decisions about
the starting age and frequency of screening for women at differ-
ent levels of risk. Recent discoveries in the field of breast cancer
genetics may hold the potential to guide risk-based screening
strategies. The risk of developing breast cancer approximately
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breast cancer (5). Approximately 20% of the familial risk is at-
tributable to high or moderate penetrance mutations in genes,
including BRCA1, BRCA2, PALB2, ATM, and CHEK2 (6,7). The
remaining 80% is due to a combination of more common varia-
tions in the DNA sequence (single nucleotide polymorphisms
[SNPs]). Currently, about 313 common SNPs have been identified
as being associated with breast cancer risk (8). Although these
individual variants are associated with small to modest in-
creased risk, their combined effects considered as a polygenic
risk score (PRS) could be useful in targeting screening strategies
based on risk (9,10).
Two ongoing trials, My Personal Breast Screening and the
Women Informed to Screen Depending on Measures of Risk
trial, are presently testing age-based vs risk-based screening
approaches that include genetic markers and family history
information, but results are not expected until 2024-2025 (11).
A recent study in the United Kingdom modeled the use of PRS
to determine the cost-effectiveness of screening women trien-
nially above a certain risk threshold (12). However, to our
knowledge, there are no studies that have compared the im-
pact of screening strategies tailored to risk based on family
history of breast cancer and polygenic risk combined. To fill
this clinical gap, 2 established Cancer Intervention and
Surveillance Modeling Network models that were used to in-
form the current USPSTF breast cancer screening guidelines
(13) were used to estimate the lifetime effects of screening
based on family history status and polygenic risk (2). The
results are intended to support conversations between women
and their healthcare providers about the benefits and harms
of starting screening before the age of 50 years. The findings
could also provide data to inform policy discussions about
risk-tailored screening guidelines.
Methods
This modeling research used deidentified, publicly available
data and was considered human participants exempt by the
Georgetown University Institutional Review Board, the institu-
tional review board of record.
Model Overview
Breast cancer simulation models developed by the Erasmus
University Medical Center (14) and the Georgetown University-
Albert Einstein College of Medicine (15) were used to evaluate
the lifetime effects of different risk-tailored screening. Briefly,
the models projected the lifetime effects of different screening
strategies among the 1985 US female birth cohort. This cohort
was carefully chosen to make this analysis relevant for women
who are now younger than the age of 50 years making choices
about screening informed by their breast cancer family history
and PRS.
The models portrayed breast cancer molecular subtype–spe-
cific incidence and mortality based on estrogen receptor and
HER2 status (16). The models included ductal carcinoma in situ
(DCIS), where the majority of DCIS progressed to invasive breast
cancer, and the rest remained nonlethal as DCIS due to slow
progression rates. Screen detection of breast cancer was mod-
eled using age-, first screen–, screening round–, and interval-
specific digital mammography sensitivity and specificity by
breast density group (low [fatty and scattered density] and high
[heterogeneous and extremely dense]) based on Breast Cancer
Surveillance Consortium data for women aged 30-74 years (17).
We made the simplifying assumption that the distribution of
breast density was independent of PRS and family history
status.
Screening benefits such as breast cancer deaths averted or
greater survival occurred with tumor detection in earlier stages
or at smaller tumor sizes compared with that expected without
screening. Screening occurred only in the ages specified by the
screening strategy; outside of this screening window, cancers
can only be diagnosed due to symptoms. At any time, women
diagnosed with breast cancer could die of the disease or com-
peting other-cause mortality. Overdiagnosis was defined as
screen-detected DCIS and invasive cases that would not have
been detected in the absence of screening because of lack of
progressive potential or death from competing mortality. In our
past research, biennial screening from ages 50 to 74 years
resulted in 40% (Model GE) to 60% (Model E) of DCIS cases being
overdiagnosed (18), with DCIS accounting for 90% of all over-
diagnosed cases.
To evaluate the potential efficacy of different screening
strategies, the models assumed that all women received genetic
testing and, if diagnosed with cancer, received molecular sub-
type–specific adjuvant therapy. Treatment effects on survival
by tumor subtype were based on systematic reviews of treat-
ment effectiveness trials (19). Model details and input parame-
ters are summarized in the Supplementary Methods and
Supplementary Tables 1 and 2 (available online), and model val-
idation has been described elsewhere (13,16,20,21).
Screening Strategies
Risk-based digital mammography screening strategies varied by
age at initiation (30, 35, 40, 45, or 50 years) and screening inter-
val (annual, biennial, triennial, and hybrid combinations).
Table 1. Prevalence and risk level according to FH of BC and the 313-
SNP PRS
BC risk and prevalence





FH positive between 30 and 39 y 2.19 (1.72 to 2.77) 4.7
FH positive between 40 and 49 y 1.73 (1.74 to1.93) 4.2
FH positive between 50 and 64 y 1.39 (1.30 to 1.48) 5.9
FH positive at age 65 y or older 1.34 (1.23 to 1.46) 2.3
No positive FH in life 0.79 (0.67 to 0.91) 82.9
Polygenic risk groupsb
1 0.0 < PRS  0.5 13.2
2 0.5 < PRS  1.0 46.7
3 1.0 < PRS  1.5 25.3
4 1.5 < PRS  2.0 9.3
5 2.0 < PRS  3.0 4.7
6 3.0 < PRS  5.0 0.7
7 5.0 < PRS  10.0 0.0
aBC risk data by family history status are from the Collaborative Breast Cancer
Study (22). A positive first-degree FH was modeled as an increase in risk at the
first age-year of each age group. Risk is age specific and relative to the popula-
tion average in which some women have but most do not have a BC family his-
tory. Thus, women in the “no positive FH in life” group have a relative risk below
the population average of 1. BC ¼ breast cancer; CI ¼ confidence interval; FH ¼
family history; PRS ¼ polygenic risk score; SNP ¼ single nucleotide
polymorphism.
bSeven risk groups were established based on the 313-SNP polygenic risk score.
For example, women in the 1.5<PRS  2.0 group have a 1.5-2.0 increased risk of
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Hybrid strategies consisted of screening annually before age 50
years and biennially starting at age 50 years. We compared the
results of these strategies with those expected using 3 US
screening guidelines, including the USPSTF (biennial screening
at ages 50-74 years), the American College of Radiology (annual
screening starting at age 40 years), and the ACS (annual screen-
ing from ages 45 to 54 years, followed by a choice to continue bi-
ennial screening at age 55 years) (2-4). We made the simplifying
assumption that all women in the ACS screening strategy
switched to biennial screening at age 55 years; otherwise the
ACS and ACR strategies would be identical. Although the ACR
and ACS guidelines do not specify stopping ages, we used
74 years as the upper age of screening so there was comparabil-
ity across screening approaches. Note that in biennial or trien-
nial strategies starting at age 45 or 55 years, the last screen
occurred at age 72 or 73 years, respectively.
Risk Stratification Based on Family History
We defined 5 family history groups: women who learned in age
ranges 30-39 years, 40-49 years, 50-64 years, and 65þ years that
they had a first-degree relative with breast cancer; and women
with no family history of breast cancer in their lifetimes. The
age-specific distribution of family history in the National Health
Interview Survey and associated risk levels observed in the
Collaborative Breast Cancer Study (22) were used to model
breast cancer risk related to family history (Table 1).
Risk Stratification Based on Polygenic Risk
Stratification of women by polygenic risk was based on a PRS
for all subtypes combined generated from 313 SNPs. The SNP se-
lection was based on analysis of data from 69 studies and vali-
dated in 10 studies from the Breast Cancer Association
Consortium (8). The PRS is based on a multiplicative risk model
for the joint effects of the breast cancer SNPs and is defined as
the sum of risk alleles weighted by their effect size as estimated
in the combined European ancestry genome wide association
studies data (8). The performance of this model has been vali-
dated in an external data set and proved to be a reliable predic-
tor of breast cancer risk in women with and without a family
history of breast cancer. The area under the receiver operator
characteristic curve that measures the discriminatory ability of
this PRS is 0.64. The women in the top 1% of the distribution
have a predicted risk approximately fourfold greater than the
risk in the middle quintile. The lifetime risk of breast cancer in
the top 10% of the PRS was 32.6%.
We modeled the distribution of breast cancer risk relative to
the average woman without a family history (RR*) as a function
of polygenic risk and family history and age:










where FHx is an indicator for first-degree family history of
breast cancer (yes¼ 1, no¼ 0), li is the log relative risk of family
history (adjusted for polygenic effects), and rii is the log relative
risk associated with a 1-SD change in the PRS in age group i. The
values for li and ri were obtained from the original publication
by Mavaddat (8) and are included in Supplementary Table 3
(available online). The distribution of breast cancer relative risk
as a function of the PRS is displayed in Supplementary Figure 1
(available online). We established 7 PRS groups spanning risk
levels from 0 to 10 times the US population average. Using the
cut-off risk levels of the 7 defined groups, we calculated the
number of women in each risk group (Table 1).
The breast cancer risk levels and prevalences based on the
313-SNP PRS and family history status combined are summa-
rized in Supplementary Table 4 (available online).
Analysis
We examined 47 potential risk groups: 5 family history, 7 poly-
genic risk, and 35 combinations of both. First, we estimated the
harms (overdiagnoses and false positives) and benefits (life-
years gained and breast cancer deaths averted) of the 3 compar-
ator screening guidelines (USPSTF, ACS, and ACR). Next, we esti-
mated the harms and benefits of the screening strategies based
on age of initiation (30, 35, 40, 45, and 50 years) and interval (an-
nual, biennial, triennial, and hybrid intervals) in each of the 47
risk groups.
To assess the impact of risk-based screening, we analyzed
which set of screening strategies maximized the total number
of life-years gained under the constraint of maintaining a simi-
lar, or better, ratio of life-years gained per mammogram as seen
with the screening guidelines, that is, the benchmark. The over-
all population impact of risk-based screening was quantified by
adding the outcomes in the individual risk groups based on
their proportions in the population. We used the USPSTF guide-
line as our base case and included the ACS and ACR guidelines
as secondary comparators. Individual model outcomes are in-
cluded in Supplementary Tables 5-7 (available online).
Sensitivity Analyses
Part of the additional benefits of risk-based screening strategies
may accrue simply from an increased number of screens.
Therefore, we analyzed what the effects of polygenic risk-based
screening would be if the total number of screens were con-
strained to the number performed in the USPSTF recommenda-
tion. All screening strategies were simulated in each PRS group,
and we assessed the set of strategies that maximized the overall
number of life-years gained across PRS groups under the fixed
number of mammograms constraint.
Results
Breast Cancer Screening Guidelines
If women of average breast cancer risk were screened according
to the USPSTF guideline (vs no screening), the models project an
average of 118 life-years gained (model range ¼ 103-133), 7
(model range ¼ 6.4-6.9) breast cancer deaths averted, 15 (model
range ¼ 12.1-16.9) overdiagnoses, and 920 (model range ¼ 918-
921) false-positive mammograms per 1000 women screened
over their lifetimes vs no screening. If the ACS or ACR guidelines
were followed, there were 61% or 178% more mammograms, re-
spectively, than in the USPSTF guideline due to early starting
ages and more frequent screening, resulting in substantial
increases in benefits but also in harms (Table 2).
Breast Cancer Family History
If women with a breast cancer family history started biennial
screening at age 40 years (vs 50 years) based on the USPSTF
guideline, the life-years gained would increase by 36% (model
range ¼ 29%-40%) from 168 to 229 life-years gained, and 20%
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averted per 1000 women screened (Table 3). However, overdiag-
noses would increase by 21% (model range ¼ 17%-23%) from
16.8 to 20.3 overdiagnoses and false positives by 63% (model
range ¼ 62%-64%) from 902 to 1468 per 1000 women screened.
Women with a positive family history in their 30s or 40s who
followed the ACR or ACS guidelines to begin screening in the
40s would have a better ratio of life-years gained to overdiagno-
sis than those who followed the USPSTF guideline (Table 3;
Figures 1 and 2).
Polygenic Breast Cancer Risk
In each polygenic risk group, the ACR guideline resulted in
the greatest number of life-years gained and breast cancer
deaths averted because it is the most intensive screening
schedule, but this strategy was also associated with more
overdiagnoses and false positives than the ACS and USPSTF
guidelines (Table 4). There were several PRS-tailored screen-
ing strategies that had comparable or greater benefits than
current guidelines, overall increasing life-years gained by an
additional 20% (118 [Table 2] to 141 [Table 5]) and breast can-
cer deaths averted by 11% (6.7 [Table 2] to 7.4 [Table 5]) com-
pared with the USPSTF guideline. The harms increased by
10% (14.5 to 16.0) more overdiagnoses and 26% (920 to 1156)
more false positives.
Benefits increased steeply relative to the USPSTF guideline
as polygenic risk increased, so that women with 3 times or
higher risk than average could begin screening at age 30 or
35 years, and those with greater than average risk (but <3 times
the risk) could initiate screening at age 40 years. In addition, the
lowest risk group could be screened triennially from ages 50 to
74 years. Although these benefits were associated with in-
creased harms, the ratio of benefits to harm was generally more
favorable or very similar to that seen for average-risk women
under USPSTF guidelines (Table 4).
Polygenic Risk and Breast Cancer Family History
Risk stratification using both polygenic risk and family history
was estimated to lead to 36 additional life-years gained (29%
increases), 1.2 fewer breast cancer deaths (18% increase), 2.1 ad-
ditional overdiagnoses (15% increase), and 1.16 more false posi-
tives in a women’s lifetime (27% increases) than the USPSTF
guideline (Tables 2 and 5). Overall, based on benefit to harm ra-
tios, screening based on the combination of family history and
polygenic risk generated the maximum life-years gained per
screen while having the best ratio of life-years gained to over-
diagnosed cases (Table 5).
Sensitivity Analyses
Without increasing the number of mammograms of the
USPSTF-recommended screening strategy, polygenic risk-based
screening was estimated to slightly increase the population-
level benefits and even reduce some of the harms compared
with the USPTF guideline (outcomes in Table 5 and screening
strategies in Table 6). In this scenario, women in the lowest risk
PRS group (0-0.5 the population average) were not screened,
women between 0.5 and 2.0 were screened biennially, and
above a risk of 2.0 hybrid and annual strategies were found to
be optimal. Overall, across risk groups, these strategies resulted
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deaths averted, 0.5 fewer overdiagnoses, and 26 additional false
positives compared with the USPSTF guideline (Table 5).
Discussion
This is the first collaborative modeling study to quantify the
effects of tailoring screening based on breast cancer polygenic
risk and family history. Compared with the current age-based
screening guidelines, our results indicate that risk-based
screening based on PRS has greater benefits than that based on
breast cancer family history only, but combining PRS and family
history maximizes improvement in outcomes. Among women
with twice the average population breast cancer risk, initiating
annual screening before age 50 years is likely to provide greater
benefits than harm than seen under the USPSTF guideline.
Women at the lowest end of the risk spectrum could consider
screening at triennial intervals.
Our results extend and are consistent with previous work on
risk-based screening based on classical risk factors (23,24) and
prior research in other countries. Vilaprinyo and colleagues per-
formed an analysis using 4 risk groups based on breast density,
family history, and personal history of breast biopsy to guide
screening (25). Recently, Pashayan used a life-table model to as-
sess risk-based screening in the United Kingdom based on poly-
genic risk profile (12). Like our results, both studies concluded
that risk-based screening strategies had greater benefit to harm
ratios than age-based screening.
Although our findings and the results of others lend support
to risk-based breast cancer screening, our approach was unique
in evaluating whether the associated increases in benefits of
Table 3. Model average benefits, harms, and benefit to harm ratios for screening based on breast cancer family history per 1000 women
screened
Risk group



















USPSTF Bi 50-74 y 10 814 168 9.3 16.5 892 0.0156 10.18 0.0104
ACS An 45-54 y,
Bi 55-74 y
17 499 222 11.0 19.2 1622 0.0127 11.51 0.0068
ACR An 40-74 y 30 173 284 13.7 25.6 2830 0.0094 11.09 0.0049
BC FH Bi 30-74 y 20 528 254 11.9 21.7 2079 0.0124 11.73 0.0057
Positive FH
age 40-49 y
USPSTF Bi 50-74 y 10 904 168 9.3 16.7 901 0.0154 10.03 0.0104
ACS An 45-54 y,
Bi 55-74 y
17 635 221 11.0 19.4 1635 0.0125 11.34 0.0067
ACR An 40-74 y 30 406 280 13.6 25.9 2851 0.0092 10.79 0.0048
BC FH Bi 40-74 y 15 713 229 11.3 20.3 1468 0.0145 11.28 0.0077
aThe primary analysis focuses on screening decisions among women under the age of 50 years. Outcomes among women with a BC FH after age 50 years are included
in the Supplementary Material (available online). An ¼ annual; ACR ¼ American College of Radiology; ACS ¼ American Cancer Society; BC ¼ breast cancer; bi ¼ biennial;
FH ¼ family history; LYG ¼ life-years gained; USPSTF ¼ United States Preventive Services Task Force.
bThe LYG and BC deaths averted are relative to the life-years and BC deaths of women at the same level of age-specific BC risk who are never screened.
Figure 1. The number of mammograms and life-years gained associated with different screening strategies among women who learned at age 40 years about a positive
first-degree family member with breast cancer. Results from exemplary Model E per 1000 women screened. The estimated harms and benefits associated with these
screening strategies are displayed in Figure 2. The underlined strategies are the commonly followed guidelines of the United States Preventive Services Task Force, the
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risk-based screening were merely attributable to more screen-
ing examinations. When we constrained the number of mam-
mograms, the benefits of risk-based screening moderately
persisted and overdiagnoses decreased compared with those
seen with the USPSTF guideline. This suggests that allocation of
mammography resources across age groups based on risk
would be an efficient approach to maximize the benefits of
screening programs.
Implementing breast cancer screening based on polygenic
risk and family history status would require a one-time saliva
sample to determine polygenic risk. The result, together with a
questionnaire about family history, could assist women in mak-
ing choices about more personalized screening options. Ethical
aspects of genetic testing such as patient autonomy, accessibil-
ity, and increased worry about screening outcomes should be
considered before the implementation of polygenic risk-based
screening strategies.
Although cost-effectiveness analysis is beyond the scope of
this paper, the current commercial laboratory cost of polygenic
risk testing is currently $100-$150. This cost is expected to de-
crease with technology advances and economies of scale. The
ultimate feasibility of implementing risk-based screening will
depend in part on how much the added costs of testing,
counseling, and screening will be offset by savings from less
screening in low-risk women and decreases in costs of cancer
care from earlier diagnoses among women destined to develop
breast cancer.
This study has several important strengths, including con-
sistent results across 2 well-established simulation models, use
of US national data, and evaluation of a 313-SNP PRS and family
history information to personalize breast cancer screening.
There are also several caveats that should be considered in eval-
uating the results. First, we did not explicitly model the effects
of rare, but higher risk variants in genes such as BRCA1, BRCA2,
PALB2, CHEK2, or ATM, which are particularly relevant among
young women under the age of 50 years. Carriers of high-risk
mutations in these genes are typically advised to undergo an-
nual screening with both MRI and mammography (26). Second,
although we account for tumor natural history by estrogen re-
ceptor and HER2 status, the models assumed that polygenic risk
did not directly affect tumor progression (27,28) or mode of de-
tection (29). Third, we did not consider screening after age
74 years or costs and quality-adjusted life-years. These will be
important to include in future research. Fourth, we did not con-
sider risk related to second-degree family members with breast
cancer due to data limitations. Fifth, to test the efficacy of risk-
based screening, we assumed perfect uptake of genetic testing,
screening, and receipt of treatment. Actual population impact
will be lower. Sixth, the effectiveness of screening in combina-
tion with treatment in women under age 40 years has been
assessed in case-control studies but not in a randomized con-
trolled trial. Finally, although we considered the effects of breast
density on mammography performance, it will be important to
A B
C D
Figure 2. Harms and benefits associated with different screening strategies among women who learned at age 40 years about a positive first-degree family member
with breast cancer. Estimates of Model E per 1000 women screened. The underlined strategies are the commonly followed guidelines of the United States Preventive
Services Task Force (USPSTF), the American Cancer Society (ACS), and the American College of Radiology (ACR). The figure shows (A) life-years gained vs overdiagnosed
breast cancers; (B) breast cancer deaths averted vs overdiagnosed breast cancers; (C) life-years gained vs false-positive mammograms; and (D) breast cancer deaths














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































edical Library user on 28 O
ctober 2021
conduct future analyses that consider joint distributions of
breast density, PRS, and family history as the data evolve.
Overall, this study demonstrated that compared with follow-
ing general population guideline strategies for women of aver-
age risk, risk-tailored screening has the potential to prevent
more breast cancer deaths and extend lives for identifiable
groups of women at high risk due to their breast cancer family
history and polygenic risk.
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bThe constrained risk-based screening approach represents a scenario where the number of screens of the United States Preventive Services Task Force screening
guidelines (top row) was not increased but rather was redistributed across the population based on the PRSs (strategies given in Table 6). The number of screens do not
exactly match because all women in each risk group were assigned to one of the screening strategies listed in the Methods section.
Table 6. Screening strategies used in the sensitivity analysis
Polygenic risk group Screening strategya
Polygenic risk group 1 (0.0 < RR < 0.5) No screening
Polygenic risk group 2 (0.5 < RR < 1.0) Biennial 50-74 y
Polygenic risk group 3 (1.0 < RR < 1.5) Biennial 45-74 y
Polygenic risk group 4 (1.5 < RR < 2.0) Biennial 45-74 y
Polygenic risk group 5 (2.0 < RR < 3.0) Hybrid 40-74 yb
Polygenic risk group 6 (3.0 < RR < 5.0) Hybrid 40-74 yb
Polygenic risk group 7 (5.0 < RR < 10.0) Annual 30-74 y
aThe set of screening strategies in this column followed from a constrained opti-
mization that maximized the overall number of life-years gained by simulating
all combinations of screening strategies under the overall constraint of using
not more mammograms as seen in the United States Preventive Services Task
Force guideline. RR ¼ relative risk.
bThe hybrid consists of annual screening from ages 40 to 49 years and biennial
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